BiotechTube

SHR7280 tablets

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Female Subjects Undergoing COH in ART to Prevent Early Ovulation

Conditions

Female Subjects Undergoing COH in ART to Prevent Early Ovulation

Trial Timeline

Mar 6, 2022 → Aug 3, 2023

NCT ID
NCT05082233

About SHR7280 tablets

SHR7280 tablets is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Female Subjects Undergoing COH in ART to Prevent Early Ovulation. The current trial status is completed. This product is registered under clinical trial identifier NCT05082233. Target conditions include Female Subjects Undergoing COH in ART to Prevent Early Ovulation.

What happened to similar drugs?

2 of 15 similar drugs in Female Subjects Undergoing COH in ART to Prevent Early Ovulation were approved

Approved (2) Terminated (0) Active (13)
🔄Gemcitabine + liposomal doxorubicinEli LillyPhase 3
✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
🔄Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
🔄Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
🔄Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06949124Phase 1Completed
NCT05082233Phase 2Completed

Competing Products

20 competing products in Female Subjects Undergoing COH in ART to Prevent Early Ovulation

See all competitors
ProductCompanyStageHype Score
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
ASP3325 + PlaceboAstellas PharmaPhase 1
29
EnsitrelvirShionogiPhase 1
29
Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
39
Gemcitabine + Paclitaxel + CarboplatinEli LillyPhase 3
40
Abemaciclib 50 MG; 150mg 1-0-1 per osEli LillyPhase 3
44
Abemaciclib, durvalumab and aromatase inhibitorEli LillyPhase 1
21
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
29
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
29
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
40
SHR3162Jiangsu Hengrui MedicinePhase 1
25
AZD3293 + PlaceboAstraZenecaPhase 1
29
Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + PlacebosAstraZenecaPhase 3
40
AZD2516 + PlaceboAstraZenecaPhase 1
29
Durvalumab + TremelimumabAstraZenecaPhase 2
39
Dapagliflozin + Metformin + Dapagliflozin + MetforminAstraZenecaPhase 1
29
AZD4901 (oral) + Placebo to match AZD4901AstraZenecaPhase 2
35